Seneca Therapeutics
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
202 Saint Andrews Ct, Blue Bell, Pennsyl...Website
www.senecatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Seneca Therapeutics
Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The first product anticipated to be in later stage clinical trials in 2021 is SVV-001 itself. SVV-001 is targeted immunotherapy that selectively kills cancer cells expressing the SVV-001's receptor, TEM-8, and stimulates the immune system to attack the tumor. SVV-001 is demonstrated to synergize with immune checkpoint inhibitors and other cancer agents to significantly benefit more cancer patients.Explore more
Seneca Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Seneca Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Seneca Therapeutics
Check if Seneca Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Seneca Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Seneca Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Seneca Therapeutics has new funding data
Check out if Seneca Therapeutics is spiking on competitors!
Product Launch: Get notified when Seneca Therapeutics launches new products
Seneca Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Seneca Therapeutics
Find 2 more new buyers
Compare Similar Companies to Seneca Therapeutics
Compare insights from companies similar to Seneca Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.5M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Seneca Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Seneca Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Seneca Therapeutics.
Seneca Therapeutics financials insights
Gather financial insights about Seneca Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$5M
Seneca Therapeutics Tech Stack
A closer look at the technologies used by Seneca Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Seneca Therapeutics News & Media
Dr. Paul Hallenbeck, CSO and President of Seneca Therapeutics to Present at World Vaccine Congress November 28, 2023
PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today Dr. Paul Hallenbeck will present a talk titled “Facilitating multiple deliveries of therapeutic viruses by exploiting natural methods of evading neutralizing immunity”, during the World Vaccine Congress in Santa Clara, CA on November 28, 2023. In his talk, Dr. Hallenbeck will present data on the development of multiple IV technology for SVV-001, a clinical stage oncology product. “Seneca believes that having both multipleSeneca Therapeutics Announces Publication of TEM8 Review Article “TEM8 in Oncogenesis” in Cells Journal
PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc., announced today the publication of “TEM8 in Oncogenesis” in Cells. The authors are Dr. Samuel Kareff and Dr. Aman Chauhan from Sylvester Cancer at University of Miami, Dr. Virginia Corbett from Mt. Sinai Tisch Cancer Center and Dr. Paul Hallenbeck from Seneca Therapeutics. “In the article, we underline TEM8’s prognostic and predictive abilities in various solid tumors by (1) highlighting its association with more aggressive disease bioloSeneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors | Business Wire
Seneca Therapeutics, Inc. (STI), today announced the appointment of Cuong Do, MBA to its Board of Directors.Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors
PHILADELPHIA--(BUSINESS WIRE)--Seneca Therapeutics, Inc. (STI), today announced the appointment of Cuong Do, MBA to its Board of Directors. "Cuong has successfully financed and led several life science biotech companies across a range of therapeutic areas, and we are extremely excited to welcome him to our Board," said James Hussey, Chief Executive Officer of Seneca Therapeutics, Inc. "Cuong’s extensive executive leadership experience, together with his strategic expertise, will help guide us a
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Seneca Therapeutics
Sign Up For FreeTo access detailed company insights
Seneca Therapeutics, Inc. (Seneca) is developing a pipeline of novel cancer agents using the nonpathogenic Seneca Valley Virus isolate 001 (SVV-001). The first product anticipated to be in later stage clinical trials in 2021 is SVV-001 itself. SVV-001 is targeted immunotherapy that selectively kills cancer cells expressing the SVV-001's receptor, T... Read More
